Recombinant PCSK9 (Bococizumab Biosimilar) antibody
Research Grade
Reactivity: Human
ELISA
Host: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Target See all PCSK9 (Bococizumab Biosimilar) products
- PCSK9 (Bococizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
-
Mammalian Cells
- Expression System
- Mammalian cells
-
Clonality
- Monoclonal
-
Conjugate
- This PCSK9 (Bococizumab Biosimilar) antibody is un-conjugated
-
Application
- ELISA
- Purpose
- Bococizumab Biosimilar - Anti-PCSK9, NARC1, PC9 mAb
- Characteristics
- Antibody Type: IgG2-kappa
- Purification
- Recombinant antibody expressed in mammalien cells and purified.
- Grade
- Research Grade
- Isotype
- IgG2
-
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS pH 7.5
- Storage
- -80 °C
- Storage Comment
- store at -80°C
-
- Target
- PCSK9 (Bococizumab Biosimilar)
- Abstract
- PCSK9 (Bococizumab Biosimilar) Products
- Target Type
- Biosimilar
- Background
-
PF-04950615,RN-316
Bococizumab is a monoclonal antibody that was development by Pfizer targeting proprotein convertase subtilisin kexin type 9 (PCSK9). Bococizumab has been investigated for the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia. - CAS-No
- 1407495-02-6
-
You are here:
